

Enhancing the antioxidant characteristics of phenolic acids by their conversion into cholinium salts

Tânia Sintra, Andreia Luís, Samuel Rocha, Ana I. M. C. Lobo Ferreira, Fernando Gonçalves, Luis M. N. B. F. Santos, Bruno M. Neves, Mara G. Freire, Sonia P.M. Ventura, and Joao A.P. Coutinho

ACS Sustainable Chem. Eng., **Just Accepted Manuscript** • DOI: 10.1021/acsuschemeng.5b00751 • Publication Date (Web): 27 Aug 2015

Downloaded from <http://pubs.acs.org> on August 27, 2015

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



Enhancing the antioxidant characteristics of phenolic acids by their conversion into cholinium salts

Tânia E. Sintra[†], Andreia Luís[†], Samuel N. Rocha[†], Ana I. M. C. Lobo Ferreira[‡], Fernando Gonçalves[§], Luís M. N. B. F. Santos[‡], Bruno M. Neves^{||}, Mara G. Freire^{†}, Sónia P. M. Ventura[†] and João A. P. Coutinho[†]*

[†] CICECO - Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal

[‡] CIQUP, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal

[§] CESAM, Department of Biology, University of Aveiro, 3810-193 Aveiro, Portugal

^{||} QOPNA, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal

[‡] Centre for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal

*Corresponding author: e-mail address: maragfreire@ua.pt

KEYWORDS: Antioxidant salts, ecotoxicity, cytotoxicity, solubility, anti-inflammatory activity

1
2
3 **ABSTRACT:** Due to the close relation between oxidative stress and a plethora of inflammatory
4 diseases, antioxidants have received an increased attention for incorporation into dermatological
5 products. Their use and absorption is however limited by their low solubility in water-rich
6 formulations. Herein, a set of novel cholinium-based salts, namely dicholinium ellagate and
7 cholinium caffeate, syringate, vanillate, gallate and salicylate were synthesized and characterized.
8 Their melting and decomposition temperatures, water solubility, and toxicological, antioxidant,
9 cytotoxicity and pro-/anti-inflammatory activities were addressed. These new salts, exclusively
10 composed of ions derived from natural sources, display a high thermal stability – up to 150 °C.
11 The synthesized compounds are significantly more soluble in water (in average, 3 orders of
12 magnitude higher) than the corresponding phenolic acids. Furthermore, they present not only
13 similar but even higher antioxidant and anti-inflammatory activities, as well as comparable
14 cytotoxicity and lower ecotoxicity profiles than their acidic precursors. Amongst all the
15 investigated salts, dicholinium ellagate is the most promising synthesized salt when considering
16 the respective antioxidant and anti-inflammatory activities. Since all the synthesized salts are
17 based on the cholinium cation, they can further be envisaged as essential nutrients to be used in
18 oral drugs.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **INTRODUCTION**

43
44
45
46 The human skin is constantly exposed to both endogenous and environmental pro-oxidant
47 agents, leading to the formation of highly noxious reactive oxygen species (ROS). ROS-
48 mediated oxidative damage includes a wide variety of pathological effects, such as DNA
49 modification, lipid peroxidation, as well as the activation of inflammatory pathways. To
50 minimize these deleterious effects, mammalian skin cells have antioxidant defense mechanisms,
51
52
53
54
55
56
57
58
59
60

1
2
3 which comprise enzymatic and non-enzymatic antioxidant agents.¹⁻² However, these systems
4 may not be enough to ensure the skin barrier integrity.³ In this context, antioxidants have found
5 an increased interest as constituents of dermatological pharmaceutical formulations and skin care
6 products.⁴⁻⁵ In both of these products there is a preference for antioxidants from natural rather
7 than synthetic sources.⁶ Phenolic compounds are the most abundant secondary metabolites of
8 plants, being recognized by their antioxidant and anti-inflammatory properties. These chemical
9 compounds have one or more aromatic rings, with one or more hydroxyl groups directly bonded,
10 and which can donate a hydrogen atom or an electron to a free radical, being thus ideal structures
11 for free radical scavenging. Naturally available phenolic acids include gallic, caffeic, syringic
12 and vanillic acids, typically present in sources such as fruits and vegetables.⁷⁻⁸ Nevertheless, the
13 limited aqueous solubility of some of these phenol-based antioxidants represents a major
14 drawback when envisaging their incorporation into water-rich dermatological formulations or for
15 their absorption and transport in body fluids. To overcome this limitation, cholinium-based salts
16 appear as promising candidates if based in compounds with antioxidant features aiming at
17 enhancing their water solubility. The pioneering synthesis of cholinium salicylate ([Chol][Sal])
18 led to an increase in the water solubility (when compared with the salicylic acid precursor), while
19 maintaining its anti-inflammatory, analgesic and antipyretic properties.⁹⁻¹⁰ Actually, [Chol][Sal]
20 is an active pharmaceutical ingredient currently used in various medicinal products, namely
21 Bonjela, Arthropan and Bucagel[®].¹¹
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Cholinium chloride, an essential nutrient, has been receiving considerable attention due to its
50 biocompatible and “non-toxic” nature.¹²⁻¹⁵ A significant number of cholinium salts has been
51 reported coupled with a wide range of anions, such as amino acid-,¹⁶⁻²⁰ carboxylic acid-,²¹⁻²⁵ and
52 good’s-buffers-based anions.²⁶ In fact, the anion selection has been carried out according to
53
54
55
56
57
58
59
60

1
2
3 specific tasks for which cholinium-based salts can be used and have demonstrated an enhanced
4 potential. Distinct applications have been suggested, namely in catalysis,¹⁶ in photodynamic
5 therapy,²⁷ in electrical and pH-sensitive drug delivery systems,²⁸ as crosslinking agents for
6 collagen-based materials,²³ as major solvents in the pre-treatment and dissolution of biomass,²⁹
7 as co-substrates for microorganisms in the degradation of dyes,¹³ and as self-buffering
8 compounds for the extraction and purification of biologically active molecules.²⁶ Nevertheless,
9 to the best of our knowledge, cholinium-based salts with remarkable antioxidant activities have
10 not been reported hitherto.

11
12 In this work, a series of new cholinium-based salts with antioxidant and anti-inflammatory
13 features were synthesized and characterized. Five anions with antioxidant and anti-inflammatory
14 characteristics, namely gallate, caffeate, vanillate, syringate and ellagate, were conjugated with
15 the cholinium (2-hydroxyethyl)trimethylammonium) cation. Additionally, [Chol][Sal] was also
16 synthesized by neutralization to compare its antioxidant performance with the new cholinium-
17 based salts studied in this work. The antioxidant activity of these compounds was investigated
18 using the 2,2-diphenyl-2-picrylhydrazyl hydrate (DPPH) radical scavenging assay and compared
19 with the archetypal ascorbic acid - a well-known antioxidant.³⁰⁻³² Their physicochemical
20 properties, namely melting point, decomposition temperature and water solubility were also
21 assessed, as well as their impact towards *Vibrio fischeri*, a standard marine luminescent bacteria
22 (Microtox[®] assay).³³ Finally, the impact of these novel antioxidant salts on mammalian cells was
23 evaluated. For that purpose, the three cholinium-based salts which have shown a better
24 performance on the DPPH radical scavenging assay were chosen (cholinium gallate, cholinium
25 caffeate and cholinium ellagate), and their cytotoxicity and pro-/anti-inflammatory activities
26 were evaluated in Raw 264.7 and HaCaT mammalian cell lines.

EXPERIMENTAL SECTION

Materials. Six cholinium-based salts with antioxidant and/or anti-inflammatory properties were synthesized, namely [Chol][Gal], (2-hydroxyethyl) trimethylammonium 3,4,5-trihydroxybenzoate; [Chol][Sal], (2-hydroxyethyl) trimethylammonium 2-hydroxybenzoate; [Chol][Caf], (2-hydroxyethyl) trimethylammonium (E)-3-(3,4-dihydroxyphenyl)acrylate; [Chol][Van], (2-hydroxyethyl) trimethylammonium 4-hydroxy-3-methoxybenzoate, [Chol][Syr], (2-hydroxyethyl) trimethylammonium 4-hydroxy-3,5-dimethoxybenzoate; [Chol]₂[Ell], di((2-hydroxyethyl) trimethylammonium) 3,8-dihydroxy-5,10-dioxo-5,10-dihydrochromeno[5,4,3-*cde*]chromene-2,7-bis(olate). Their full name, acronym and chemical structure are depicted in Scheme 1. Cholinium hydroxide ([Chol]OH, in methanol solution at 45 wt%), vanillic acid (97 wt% of purity) and 2,2-diphenyl-2-picrylhydrazyl hydrate (DPPH) were acquired from Sigma-Aldrich[®]. Syringic (98 wt% of purity) and ellagic (97 wt% of purity) acids were from Alfa Aesar[®]. Salicylic (99 wt% of purity), gallic (99.5 wt% of purity) and caffeic (99 wt% of purity) acids were from Acofarma, Merck[®] and Acros Organics, respectively. Methanol (HPLC grade), acetone (99.9 wt% of purity), and ethyl acetate (99 wt% of purity) were from VWR. The water used was double distilled, passed by a reverse osmosis system and further treated with a Milli-Q plus 185 water purification apparatus. The human keratinocyte cell line HaCaT, obtained from DKFZ (Heidelberg), was kindly supplied by Doctor Eugénia Carvalho (Centre for Neuroscience and Cell Biology, University of Coimbra, Portugal). Raw 264.7 (ATCC number: TIB-71), a mouse macrophage cell line, was kindly supplied by Doctor Otilia Vieira (Centre for Neuroscience and Cell Biology, University of Coimbra, Portugal).

Synthesis and characterization of cholinium salts. Six cholinium-based salts were synthesized by the neutralization of [Chol]OH with the respective acid, with a well-known antioxidant/anti-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

inflammatory character, namely the gallic, vanillic, caffeic, salicylic, syringic, and ellagic acids (Scheme 1).^{17-18, 23} The synthesis of [Chol]₂[Ell] and [Chol][Gal] has already been reported in literature, however the synthetic route here proposed is more simple.³⁴⁻³⁵ [Chol]OH (1 equivalent, 45 wt% in a methanol solution) was added drop wise to the acidic solution in methanol, with a molar excess of 1.1 equivalents, at 0 °C, under nitrogen atmosphere. Regarding the [Chol]₂[Ell] synthesis, the [Chol]OH was added to the ellagic acid solution in methanol, with a molar ratio of 2:1. The reaction mixture was stirred at room temperature, under nitrogen atmosphere, and protected from light overnight, producing the cholinium salt and water as the by-product. The solvent and water were then removed under reduced pressure. Moreover, in the synthesis of [Chol][Van], [Chol][Syr] and [Chol][Caf], the unreacted antioxidant acid accumulated in the prepared IL was eliminated with acetone (3 x 20 mL), followed by filtration to remove the cholinium salt (which is in the solid state). The same procedure was adopted for [Chol][Gal], only replacing acetone by methanol. In the synthesis of [Chol][Sal], the remaining salicylic acid was accumulated as a viscous liquid, being removed by a liquid-liquid extraction with ethyl acetate (3 x 20 mL).²⁴ Finally, the residual solvent was removed under reduced pressure and the obtained compound was dried under high vacuum for at least 48 h. The structure of all compounds synthesized was confirmed by ¹H and ¹³C NMR, IR spectroscopy and elemental analysis, showing the high purity level of all the ionic structures after their synthesis, as reported in the Supporting Information.

Thermogravimetric analysis. The decomposition temperature was determined by thermogravimetric analysis (TGA). TGA was conducted on a Setsys Evolution 1750 (SETARAM) instrument. The sample was heated in an alumina pan, under a nitrogen atmosphere, over a temperature range of 25 - 800 °C, and with a heating rate of 10 °C.min⁻¹.

1
2
3 **Differential scanning calorimetry.** Temperatures of melting transition temperature were
4 measured in a power compensation differential scanning calorimeter, PERKIN ELMER model
5 Pyris Diamond DSC, using hermetically sealed aluminum crucibles with a constant flow of
6 nitrogen (50 mL.min⁻¹). Samples of about 15 mg were used in each experiment. The temperature
7 and heat flux scales of the power compensation DSC were calibrated by measuring the
8 temperature and the enthalpy of fusion of reference materials namely benzoic acid, 4-
9 metoxybenzoic acid, triphenylene, naphthalene, anthracene, 1,3,5-triphenylbenzene,
10 diphenylacetic acid, perylene, o-terphenyl and 9,10-diphenylanthracene, at the scanning rate of 2
11 K.min⁻¹ and flow of nitrogen. Temperatures of the thermal transitions and melting temperature
12 were taken as the onset temperatures.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 **Water solubility.** The water solubility of cholinium-based salts and of the corresponding
29 antioxidant acids was determined from a saturated aqueous solution. An excess of each
30 compound was added to pure water (≈ 1 mL), and allowed to equilibrate at constant temperature
31 (25.0 \pm 0.5 °C), under constant agitation (750 rpm) for 72 hours using an Eppendorf
32 Thermomixer Comfort equipment. After the equilibration time, properly optimized in this work,
33 all samples were centrifuged at (25.0 \pm 0.5) °C in a Hettich Mikro 120 centrifuge during 20
34 minutes at 4500 rpm. Then, all samples were placed in an air bath equipped with a Pt 100 probe
35 and PID controller at the aforementioned temperature in equilibrium assays during 2 hours. To
36 determine the concentration of each cholinium salt and acid, a sample of the aqueous liquid
37 phase was carefully collected, diluted in ultra-pure water, and quantified through UV-
38 spectroscopy, using a SHIMADZU UV-1700, Pharma-Spec Spectrometer., at each λ_{max} in the
39 UV region. Their values, as well as the respective calibration curves, are reported in the
40 Supporting Information, Table S1. Triplicate measurements were carried out.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **DPPH radical scavenging assay.** The antioxidant activities of cholinium-based salts and the
4 respective acids, were determined using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical
5 scavenging assay.³⁰⁻³² The principle of the assay is based on the color change of the DPPH
6 solution from purple to yellow, as the radical is quenched by the antioxidant. When a solution of
7 DPPH is mixed with a substance that can donate a hydrogen, the reduced form of DPPH is
8 obtained, and the solution which started to be violet turns to be yellow. This change in color was
9 monitored by Visible (Vis) spectroscopy at 517 nm. Briefly, 250 μL of a DPPH solution (0.91
10 mmol.L^{-1}) in methanol was mixed with different volumes (20, 30, 40, 50, 60, 70 and 80 μL) of a
11 stock solution (with a well-known concentration) of each compound and then methanol was
12 added to complete 4 mL (final volume). The samples were kept in the dark for 30, 90 and 120
13 minutes at room temperature and then the decrease in the absorbance at 517 nm was measured.
14 The absorbance of the DPPH solution in the absence of the compounds under analysis was also
15 measured as control. Ascorbic acid was used as positive control. DPPH radical scavenging
16 activity - AA(%) - was expressed using equation (1):
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

$$36 \quad \text{AA (\%)} = (A_0 - A_1)/A_0 \times 100 \quad (1)$$

37 where A_0 is the absorbance of the control and A_1 is the absorbance of the sample at 517 nm.
38 DPPH scavenging activity is defined by the IC_{50} value - the concentration of the antioxidant
39 needed to scavenge 50% of the DPPH present in the test solution. IC_{50} values were determined
40 from the equations reported in the Supporting Information (Table S2) derived from the graphical
41 representation of the scavenging activity against the sample concentration. Triplicate
42 measurements were carried out.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Microtox[®] assay.** To evaluate the ecotoxicity of the cholinium salts synthesized, as well as of the
4
5 corresponding acids, the Standard Microtox[®] liquid-phase assay was applied. Microtox[®] is a
6
7 bioluminescence inhibition method based on the bacterium *Vibrio fischeri* (strain NRRL B-
8
9 11177) luminescence after its exposure to each sample solution at 15 °C. In this work, the
10
11 standard 81.9% test protocol was followed.³³ The microorganism was exposed to a range of
12
13 diluted aqueous solutions of each compound (from 0 to 81.9 wt%), where 100% corresponds to a
14
15 previously prepared stock solution, with a known concentration. After 5, 15, and 30 minutes of
16
17 exposure to each aqueous solution, the bioluminescence emission of *Vibrio fischeri* was
18
19 measured and compared with the bioluminescence emission of a blank control sample. Thus, the
20
21 corresponding 5 min-, 15 min- and 30 min-EC₅₀ values (EC₅₀ being the estimated concentration
22
23 yielding a 50% of inhibition effect), plus the corresponding 95% confidence intervals, were
24
25 estimated for each compound tested by non-linear regression, using the least-squares method to
26
27 fit the data to the logistic equation. Previously to Microtox[®] testing, the amount of water was
28
29 determined by Karl Fischer (KF) titration using a Metrohm 831 KF coulometric titrator. On the
30
31 basis of this parameter, the real concentration of each stock solution was corrected, thus
32
33 obtaining EC₅₀ values with higher accuracy.
34
35
36
37
38
39
40
41

42 **Evaluation of cytotoxicity.**

43 *Human keratinocyte cell line HaCaT and Raw 264.7*

44
45
46
47
48
49 Keratinocytes were cultured in a Dulbecco's Modified Eagle Medium (high glucose)
50
51 supplemented with 4 mM of glutamine, 10% heated inactivated fetal bovine serum, penicillin
52
53 (100 U.mL⁻¹) and streptomycin (100 µg.mL⁻¹), at 37 °C, in a humidified atmosphere of 95% of
54
55 air and 5% of CO₂. Raw 264.7 was cultured in an Iscove's Modified Dulbecco's Eagle Medium
56
57
58
59
60

1
2
3 supplemented with 10% of non-inactivated fetal bovine serum, penicillin (100 U.mL^{-1}), and
4
5 streptomycin ($100 \mu\text{g.mL}^{-1}$), at $37 \text{ }^\circ\text{C}$, in a humidified atmosphere of 95% of air and 5% of CO_2 .
6
7
8 Along the experiments, the cells were periodically monitored by microscope observations in
9
10 order to detect any morphological change imposed to the cells.
11

12 13 14 *Cytotoxicity tests of cholinium-based salts and the respective acids*


15
16
17 The cytotoxicity of the cholinium salts and respective acids was determined by exposing HaCaT
18
19 and Raw 264.7 cells to distinct and increased concentrations of [Chol][Gal], [Chol][Caf],
20
21 [Chol]₂[Ell], gallic acid, caffeic acid and ellagic acid (in a range of concentrations between $1 \mu\text{M}$
22
23 and $5000 \mu\text{M}$). The cells were seeded in 96-well plates and incubated during 24 hours to allow
24
25 attachment, thus enabling high-throughput screening. cholinium salts samples, formulated at
26
27 various dilutions in full-complement media, were added to the cells. A resazurin solution (10%
28
29 v/v) was added to the cells during the last 2 and 1 hour(s) of incubation for HaCat and Raw 264.7
30
31 cells, respectively. After incubation, the absorbance of resorufin (the product of the resazurin
32
33 reduction) was measured at 570 and 600 nm in a standard spectrophotometer MultiSkan Go
34
35 (Thermo Fisher Scientific, Waltham, MA, USA). The treated cells were normalized regarding
36
37 the control (untreated cells). To calculate the EC_{50} values, dose–response curves were fitted with
38
39 the non-linear least squares method using a linear logistic model. The data reported correspond
40
41 to the average of three biological independent experiments conducted in triplicate for each
42
43 compound.
44
45
46
47
48
49

50
51 **Nitric oxide (NO) measurement.** The pro- or anti-inflammatory activity of [Chol][Gal],
52
53 [Chol][Caf], [Chol]₂[Ell], gallic acid, caffeic acid and ellagic acid, was evaluated in the mouse
54
55 macrophage cell line Raw 264.7. The production of NO was measured by the accumulation of
56
57
58
59
60

1
2
3 nitrite in the culture supernatants, using a colorimetric reaction with the Griess reagent. The cells
4
5 were plated at 3×10^5 cells/well in 48-well culture plates, allowed to stabilize for 12 hours, and
6
7 then incubated with the culture medium (control), or stimulated with $1 \mu\text{g}\cdot\text{mL}^{-1}$ of
8
9 lipopolysaccharide (LPS), or with $1 \mu\text{g}\cdot\text{mL}^{-1}$ of LPS in presence of three concentrations (100
10
11 μM , 50 μM and 10 μM) of [Chol][Gal], [Chol][Caf], [Chol]₂[Ell], ellagic acid, gallic acid and
12
13 caffeic acid, for 24 hours. Briefly, 100 μL of culture supernatants were collected and diluted with
14
15 equal volume of the Griess reagent [0.1% (w/v) N-(1-naphthyl) ethylenediamine dihydrochloride
16
17 and 1% (w/v) sulfanilamide containing 5% (w/v) H_3PO_4] during 30 minutes, in the dark. The
18
19 absorbance at 550 nm was measured using a standard spectrophotometer MultiSkan Go (Thermo
20
21 Fisher Scientific, Waltham, MA, USA). Comparisons between multiple groups were performed
22
23 by One-Way ANOVA analysis, with a Bonferroni's Multiple Comparison post-test. Statistical
24
25 analysis was performed using GraphPad Prism, version 5.02 (GraphPad Software, San Diego,
26
27 CA, USA). Significance levels are as follows: *p <0.05, **p <0.01, ***p <0.001, ****p
28
29 <0.0001.
30
31
32
33
34
35
36

37 RESULTS AND DISCUSSION

38
39
40 A set of new cholinium-based salts with antioxidant features were synthesized by the
41
42 neutralization of [Chol]OH with five distinct acids with antioxidant and anti-inflammatory
43
44 characteristics, namely the gallic, vanillic, caffeic, syringic, and ellagic acids. By way of
45
46 comparison, [Chol][Sal] was also prepared. Their full name, acronym and chemical structure are
47
48 depicted in Scheme 1. All cholinium salts were obtained with high purity levels and yield – cf.
49
50 Experimental Section.
51
52
53
54
55
56
57
58
59
60



Scheme 1. Synthesis scheme and chemical structure of the cholinium-based salts prepared.

The antioxidant activity of all novel cholinium-based salts, as well as of their respective precursors, the phenolic acids, was investigated using the 2,2-diphenyl-2-picrylhydrazyl hydrate (DPPH) radical scavenging assay and compared with ascorbic acid, a well-known prototypic antioxidant. DPPH scavenging activity is usually evaluated by the IC_{50} value output, defined as the concentration of a given compound needed to scavenge 50% of DPPH present in the test solution. Taking into account the IC_{50} definition, a lower IC_{50} value reflects a better DPPH radical scavenging activity. The values depicted in Figure 1, expressed in $\mu\text{mol.L}^{-1}$, reveal that all the synthesized cholinium-based salts present a higher antioxidant activity when compared with the respective acidic precursor. This trend is particularly visible with [Chol][Van] that displays a significantly higher DPPH radical scavenging activity than vanillic acid. Therefore, these novel compounds appear as promising antioxidant candidates since lower amounts of the cholinium salts are required to reach the same antioxidant activity when compared with the

respective and traditional phenolic acids currently used. Moreover, since they are coupled to the cholinium cation, they can also be envisaged as a source of essential nutrients within the vitamin B complex – an outstanding characteristic for use either in dermatological formulations or as oral drugs.

The antioxidant activity of [Chol][Sal] and salicylic acid was tested up to a concentration of 1 mg.mL⁻¹, being impossible to determine the IC₅₀ value for any of these two compounds. Vanillic acid also requires more time to exert its antioxidant activity, being the IC₅₀ only reached after 90 and 120 minutes of exposure to DPPH. The IC₅₀ data (in μg.mL⁻¹), as well as the respective standard deviations, are provided in the Supporting Information, Table S3.





Figure 1. IC₅₀ values (μmol.L⁻¹) and respective standard deviations, after 30, 90 and 120 minutes of exposure to DPPH.

In general, for the cholinium-based salts synthesized, their antioxidant activity increases in the following order:



with $[\text{Chol}]_2[\text{Ell}]$ presenting the highest antioxidant activity.

The physicochemical properties of the antioxidant cholinium salts and respective acids, namely melting point, decomposition temperature and water solubility were additionally addressed. The melting temperatures (T_{fus}), dehydration temperature for the $[\text{Chol}][\text{Gal}]$, glass transition temperature and cold crystallization temperatures were measured by differential scanning calorimetry (DSC) data and are presented in Table 1. The onset temperatures of decomposition (T_d) were further evaluated by thermogravimetric analysis (TGA), and are reported in Table 1.

From the TGA profiles of the cholinium-based salts prepared, and of the corresponding acids (shown in the Supporting Information, Figure S1), as well as from the T_d values reported in Table 1, it is possible to conclude that all compounds studied present a high thermal stability – at least up to 150 °C. However, $[\text{Chol}][\text{Caf}]$ and gallic acid decompose immediately after their melting temperatures are reached. Amongst all the investigated cholinium-based salts, $[\text{Chol}]_2[\text{Ell}]$ is the salt with the highest thermal stability (265 °C). Cholinium-based salts also display a slightly lower thermal stability than the respective acids. $[\text{Chol}][\text{Sal}]$ appears as an exception to this pattern since it presents a higher decomposition temperature compared to salicylic acid. Taking into account that the decomposition of cholinium chloride occurs at *circa* 305°C,³⁶ the obtained results show that the anion plays a crucial role in the thermal stability of cholinium salts. Actually, the trend observed in the thermal stability of phenolic acids is similar to that corresponding to cholinium-based salts. In general, the increase in the number of substituents at the benzene ring leads to a decrease of the thermal stability, particularly by the introduction of a methoxy group.

Table 1. Thermal properties of the synthesized cholinium-based salts, namely the melting temperature (T_{fus}) and temperature of decomposition (T_d).

	[Chol] [Van]	[Chol] [Caf]	[Chol] [Syr]	[Chol] [Gal] ^a	[Chol] ₂ [Ell]	[Chol] [Sal] ^b	Van. Acid	Caf. Acid	Syr. Acid	Gal. Acid	Ell. Acid	Sal. Acid
T_{fus} / °C	169	155	150	179	259	38	210 ^c	191 ^d	207 ^f	262 ^c	287 ^d	158 ^c
T_d / °C	186.8	155.0	178.9	185.3	265.0	226.0	233.7	218.3	256.4	262.5	472.6	183.9

^aDehydration temperature = 140 °C. ^bGlass transition temperature = -56 °C; Cold crystallization temperature = -14 °C. ^cMota et al.³⁷

^dEstimated using a group-contribution method.³⁸ ^eSigma database (<http://www.sigmaaldrich.com/portugal.html>). ^fQueimada et al.³⁹

It is well-established that cholinium-based salts display, in general, a high solubility in water.⁴⁰⁻⁴¹

The water solubility of the antioxidant-cholinium salts was also determined and compared with the water solubility of their corresponding acids at 25 °C. The solubility data and the respective standard deviations are reported in Table 2. The values obtained for the phenolic acids are in close agreement with literature.^{37, 39} The results obtained for the cholinium-based salts demonstrate that these new antioxidant compounds display a solubility in water three orders of magnitude (in average) higher than the respective acidic precursors. This feature is certainly a great advantage afforded by these antioxidant salts to be incorporated into more formulations and for a widespread range of applications for which their high water solubility is relevant.

Table 2. Water solubility of the synthesized salts and of the corresponding acids (mmol.L⁻¹) at 25 °C. The respective standard deviations (std) are also presented.

Y	(Water solubility ± std) / (mmol.L ⁻¹)	
	[Chol][Y]	HY
Van	3181.40 ± 118.17	10.43 ± 0.30
Caf	2722.47 ± 63.30	3.84 ± 0.04
Syr	2793.71 ± 17.98	7.40 ± 0.02

Gal	2402.27 ± 6.09	71.33 ± 2.70
Ell^a	622.97 ± 36.98	1.26E-02 ± 3.31E-04 ^b
Sal	Completely miscible	15.66 ± 0.14

^a[Chol]₂[Ell]. ^bFrom Queimada et al.³⁹

Albeit a high water solubility of the new ionic compounds can be valuable for their incorporation into dermatological and pharmaceutical formulations, on the other hand, these may lead to an increase on their potential release into aquatic ecosystems. The legislation concerning the (eco)toxicological hazards of several chemical compounds is nowadays more stringent in Europe, and all the new substances should be evaluated a priori by REACH (Registration, Evaluation, Authorization and Restriction of Chemicals) before any industrial-scale application.⁴² Standard assays using the luminescent marine bacteria *Vibrio fischeri* are one of the most widespread toxicological bioassays used.⁴³⁻⁴⁶ The ecotoxicological impact of these cholinium-based salts was evaluated using the standard Microtox[®] acute assay. EC₅₀ values (mg.L⁻¹), the estimated concentration yielding a 50% of inhibition effect in the microorganism luminescence, were determined for the cholinium salts and the simple acids after 5, 15 and 30 minutes of exposure to the bacteria *Vibrio fischeri* - values reported in the Supporting Information file, Table S4. According to the obtained results (EC₅₀ values at 30 min of exposure time), it is possible to categorize these compounds as belonging to the following Category: Acute III according to the European Classification; as (1) “practically harmless” ([Chol][Caf], [Chol][Syr] and [Chol][Sal], with 100 mg.L⁻¹ < EC₅₀ < 1000 mg.L⁻¹); and as (2) “harmless” ([Chol][Van] and [Chol][Gal] with EC₅₀ > 1000 mg.L⁻¹).⁴⁷ On the opposite, all antioxidant acidic precursors are “moderately toxic” (with 10 mg.L⁻¹ < EC₅₀ < 100 mg.L⁻¹), according to

Passino's classification.⁴⁷ Figure 2 depicts the EC₅₀ data in mmol.L⁻¹. Their ecotoxicity increases as follows:

$$[\text{Chol}][\text{Gal}] < [\text{Chol}][\text{Caf}] \approx [\text{Chol}][\text{Van}] < [\text{Chol}][\text{Syr}] < [\text{Chol}][\text{Sal}],$$

being [Chol][Gal] the less toxic and [Chol][Sal] the most toxic cholinium-based salts, respectively. The EC₅₀ values of [Chol][Van] and [Chol][Syr] suggest that the incorporation of methoxy groups into the aromatic ring increases their ecotoxicity. Even though, in general, all the cholinium-based salts with antioxidant features also display a remarkably lower ecotoxicological impact than their precursors, which further supports their potential use at large-scale applications.




Figure 2. EC₅₀ values (mmol.L⁻¹) determined after 5, 15 and 30 minutes of *Vibrio fischeri* exposure. The error bars correspond to 95 % confidence level limits.

Taking into consideration the high antioxidant activity and/or low ecotoxicity of [Chol][Gal], [Chol][Caf] and [Chol]₂[Ell], these cholinium salts were chosen to further evaluate their *in vitro* cytotoxicity and anti-inflammatory features, by addressing their impact, as well as of the

1
2
3 corresponding acid counterparts, on the capacity of Raw 264.7 (macrophages) and HaCaT
4 (keratinocytes) to metabolize the dye resazurin. Figure 3 depicts the EC_{50} data, which represents
5 the concentration of each compound that, for 24 hours of exposure, induces a 50% decrease in
6 the cell viability.
7
8
9
10

11
12
13 [Chol][Gal] and gallic acid have similar cytotoxic profiles against Raw 264.7 (EC_{50} : 835.8 μ M
14 and EC_{50} : 590.7 μ M, respectively) and HaCaT (EC_{50} : 303.5 μ M and EC_{50} : 267.1 μ M,
15 respectively) cell lines. [Chol][Caf] causes a 50% decrease in cell viability at 2336 μ M towards
16 the macrophage cells and at 1794 μ M for the keratinocytes. These values are of similar
17 magnitude with those found for caffeic acid in macrophage cells (EC_{50} : 1996 μ M) and
18 keratinocytes (EC_{50} : 1803 μ M). For [Chol]₂[Ell] and ellagic acid it was not possible to accurately
19 determine the EC_{50} cytotoxic values due to restrictions regarding their solubility limits in cell
20 culture medium, given that the presence of salts in the cells medium leads to the cholinium salt
21 and acid precipitation. Although the [Chol]₂[Ell] presents a high water solubility, its precipitation
22 was also observed with the addition of osmotic solution during the Microtox[®] test. For the
23 maximum concentration of [Chol]₂[Ell] achieved (125 μ M), it was not observed a decrease in the
24 cell viability.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Viability of Raw 264.7 and HaCaT cells assessed as the normalized response of treated cells to untreated controls, measured by the metabolic conversion of resazurin. The data shown represents the dose-response curves of Raw 264.7 cells to: (A) [Chol][Gal] EC₅₀: 835.8 μM and Gallic Acid EC₅₀: 590.7 μM; and (C) [Chol][Caf] EC₅₀: 2336 μM and Caffeic Acid EC₅₀: 1996 μM; and HaCaT cells to (B) [Chol][Gal] EC₅₀: 303.5 μM and Gallic Acid EC₅₀: 267.1 μM; and (D) [Chol][Caf] EC₅₀: 1794 μM and Caffeic Acid EC₅₀: 1803 μM.

For all the compounds investigated, the cells survival rate decreases with the increase on the cholinium salt concentration. Overall, the obtained results demonstrate that the antioxidant cholinium-based salts possess cytotoxicity profiles over mammalian cells similar to their parent acids, allowing therefore their safe utilization in products for human healthcare.

In addition to the evaluation of the toxicity profile of the novel cholinium-based salts, it is crucial to ensure that they do not present immunostimulatory abilities when envisaged as novel products for the formulation of human care products. With this goal in mind, we further analyzed the effects of [Cho][Gal], [Chol][Caf], [Chol]₂[Ell] and the respective counterpart acids in the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

production of nitric oxide (NO) by macrophages. The production of NO results from the activation of macrophages and consequent increased expression of nitric oxide synthase, a strong pro-inflammatory mediator closely associated with numerous inflammatory diseases. As shown in Figure 4, the three concentrations tested for each compound (100 μM , 50 μM and 10 μM) barely induce the production of NO in macrophages when compared to a classical pro-inflammatory stimulus, such as bacterial lipopolysaccharide (LPS). Additionally, the investigated cholinium salts do not present a significant pro-inflammatory activity when compared with the respective acids, indicating thus that the synthesis pathway used in the present work represents a biologically safe modification.




Figure 4. Effect of cholinium-based salts and their respective acids on the NO production in macrophages for concentrations of 10 μM , 50 μM and 100 μM . The results are expressed as the amount of NO produced by the control cells maintained in a culture medium. LPS at a concentration of 1 $\mu\text{g.mL}^{-1}$ was used as a positive control. Each value represents the average value and the respective standard deviation obtained from 3 independent experiments (* $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$).

1
2
3 As some antioxidant compounds display also anti-inflammatory activity, we finally addressed
4 whether the synthesized cholinium salts and respective acids can be used in parallel as anti-
5 inflammatory drugs. To this end, an in vitro inflammatory model consisting of Raw 264.7
6 macrophages stimulated with LPS was used. Cells were pre-treated for 1 hour with 100 μ M and
7 50 μ M of the cholinium-based salts or their respective acids and then exposed to the strong
8 inflammation activator LPS. The potential anti-inflammatory activities of the studied compounds
9 were evaluated as the effect over the LPS-induced NO production (Figure 5). The prototypical
10 anti-inflammatory N-Acetyl-Cysteine (NAC) compound, as well as the nuclear factor kappa-
11 light-chain-enhancer of activated B cells (NF- κ B) inhibitors, BAY and pyrrolidine
12 dithiocarbamate (PTDC), were also used as positive controls.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 The capacity of the synthesized cholinium-based salts to inhibit the NO production is identical to
29 their parent acids. The compounds with higher anti-inflammatory activity are [Chol]₂[Ell] and
30 [Chol][Caf] which significantly inhibit the LPS-induced NO increase. Their anti-inflammatory
31 effects are however smaller than BAY and PDTC; yet, of the same order of magnitude of NAC,
32 a well-known antioxidant and anti-inflammatory molecule. It should be highlighted that although
33 the NO production is a common readout in high-throughput screening for anti-inflammatory
34 compounds, it represents only a single parameter that not completely resumes an inflammation
35 pattern. In addition to the NO inhibition, caffeic acid strongly inhibits the production of
36 prostaglandin E2, leukotrienes and pro-inflammatory cytokines, such as TNF- α , IL-1 β and IL-
37 6⁴⁸⁻⁵⁰, while the anti-inflammatory activity of ellagic acid was shown to rely on the decrease of
38 NO, IL-6, TNF- α , IFN- γ and COX-2.⁵¹⁻⁵² Therefore, it is expected that the correspondent
39 cholinium-based salts are also able to maintain these biological effects. On the other hand, we
40 observed that neither [Chol][Gal] nor gallic acid decrease the LPS-induced NO production by
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

macrophages. These results are in accordance with previous reports, where 3,4,5-trihydroxybenzoic acid (gallic acid) was shown to display a limited anti-inflammatory ability, while being more effective as an antibacterial and anticancer agent.⁵³⁻⁵⁵




Figure 5. Effect of NAC, BAY, PDTC, cholinium-based salts and their respective acids (at 100 μM and 50 μM) on the inhibition of LPS-induced NO production in macrophages. The results are expressed as the amount of NO produced relatively to cells treated with 1 μg.mL⁻¹ of LPS. Each value represents the average value and the respective standard deviation obtained from 3 independent experiments (****p<0.0001: LPS vs LPS + treatment).

CONCLUSIONS

Antioxidant cholinium-based salts with outstanding water-solubility, and anti-inflammatory activities, exclusively composed of ions derived from natural sources, were synthesized and characterized for the first time. All these compounds present a good thermal stability, at least up to 150 °C, with [Chol]₂[Ell] being the cholinium salt with the highest thermal stability (265 °C). The data obtained further reveal that these new cholinium-based salts present not only similar or even higher antioxidant and anti-inflammatory activities, as well as comparable cytotoxicity and lower ecotoxicity profiles than their respective acidic precursors. Considering the [Chol][Sal]

1
2
3 and salicylic acid, and although their anti-inflammatory profiles are well reported in the
4 literature, their antioxidant activity was tested up to a concentration of 1 mg.mL^{-1} , being
5 impossible to determine the IC_{50} value for any of these two compounds by DPPH. Then, the five
6 new cholinium-based salts display a significant added-value in terms of antioxidant activity
7 compared with [Cho][Sal]. Furthermore, the synthesized compounds are significantly more
8 soluble in water (in average, 3 orders of magnitude higher) than the corresponding acids,
9 rendering thus these new antioxidant and anti-inflammatory cholinium salts as more valuable
10 candidates in the formulation of pharmaceutical/cosmetic products. Finally, [Chol]₂[Eil] seems to
11 be one of the most promising cholinium salts here synthesized in terms of antioxidant and anti-
12 inflammatory activities. Since all synthesized compounds are based on the cholinium cation, they
13 can also be foreseen as essential nutrients for use in dermatological formulations and oral drugs.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 **Supporting Information.** Synthesis and characterization of cholinium-based salts. Calibration
34 curves used to determine the water solubility of the cholinium-based salts and of the respective
35 acids. Equations derived from the graphical representation of scavenging activity against the
36 sample concentration. IC_{50} ($\mu\text{g.mL}^{-1}$) values determined for the cholinium-based salts under
37 study and for the respective acids. TGA curves of the synthesized cholinium-based salts and of
38 the respective acidic species. EC_{50} values (mg.L^{-1}) for the antioxidant cholinium salts under
39 study and for the corresponding acids, after exposure to the *Vibrio fischeri*. This material is
40 available free of charge via the Internet at <http://pubs.acs.org>.
41
42
43
44
45
46
47
48
49
50
51
52

53 AUTHOR INFORMATION

54
55
56 **Corresponding Author**
57
58
59
60

1
2
3 *E-mail address: maragfreire@ua.pt; Tel: +351-234-401422; Fax: +351-234-370084;
4
5

6 **Author Contributions**

7
8
9 The manuscript was written through contributions of all authors. All authors have given approval
10 to the final version of the manuscript.
11
12

13 **ACKNOWLEDGMENT**

14
15 This work was developed in the scope of the project CICECO - Aveiro Institute of Materials
16 (Ref. FCT UID/CTM/50011/2013), financed by national funds through the FCT/MEC and when
17 applicable, co-financed by FEDER under the PT2020 Partnership Agreement. The authors are
18 grateful for financial support from FCT for the doctoral grant SFRH/BD/85871/2012 of T.E.
19 Sintra. and post-doctoral grant SFRH/BPD/79263/2011 of S. P. M. Ventura. M. G. Freire
20 acknowledges the European Research Council (ERC) for the Starting Grant ERC 2013-StG-
21 337753.
22
23
24
25
26
27
28
29
30
31
32

33 **REFERENCES**

- 34
35
36
37
38
39
40
41 1. Kovacic, P.; Somanathan, R., Dermal Toxicity and Environmental Contamination:
42 Electron Transfer, Reactive Oxygen Species, Oxidative Stress, Cell Signaling, and Protection by
43 Antioxidants. In *Reviews of Environmental Contamination and Toxicology*, Whitacre, D. M., Ed.
44 Springer New York: **2010**; Vol. 203, pp 119-138.
45
46
47
48
49
50
51 2. Lin, C. B.; Southall, M. D., New insights on the regulation of extracellular matrix
52 proteins during skin aging. In *Skin Aging: New Research*, **2013**; pp 23-41.
53
54
55
56
57
58
59
60

- 1
2
3 3. Briganti, S.; Picardo, M., Antioxidant activity, lipid peroxidation and skin diseases.
4
5 What's new. *J. Eur. Acad. Dermatol. Venereol.* **2003**, *17* (6), 663-669.
6
7
- 8
9 4. Podda, M.; Grundmann-Kollmann, M., Low molecular weight antioxidants and their role
10
11 in skin ageing. *Clin. Exp. Dermatol.* **2001**, *26* (7), 578-582.
12
13
- 14 5. Fuchs, J., Potentials and limitations of the natural antioxidants RRR-alpha-tocopherol, l-
15
16 ascorbic acid and β -carotene in cutaneous photoprotection. *Free Radic. Biol. Med.* 1998, *25* (7),
17
18 848-873.
19
20
- 21
22 6. Qi, H.; Zhang, Q.; Zhao, T.; Chen, R.; Zhang, H.; Niu, X.; Li, Z., Antioxidant activity of
23
24 different sulfate content derivatives of polysaccharide extracted from *Ulva pertusa* (Chlorophyta)
25
26 in vitro. *Int. J. Biol. Macromolec.* **2005**, *37* (4), 195-199.
27
28
29
- 30 7. Dai, J.; Mumper, R. J., Plant phenolics: extraction, analysis and their antioxidant and
31
32 anticancer properties. *Molecules* **2010**, *15* (10), 7313-7352.
33
34
35
- 36 8. Škrovánková, S.; Mišurcová, L.; Machů, L., Chapter three - Antioxidant activity and
37
38 protecting health effects of common medicinal plants. In *Advances in Food and Nutrition*
39
40 *Research*, Jeyakumar, H., Ed. Academic Press: **2012**; Vol. 67, pp 75-139.
41
42
43
- 44 9. Richard S., B; Lorz, E. Process for the preparation of choline salicylate. Patent
45
46 US3141035 A, 1964.
47
48
- 49 10. Broh-Kahn, R. H.; Sasmor, E. J. Choline salicylate composition and methods of use.
50
51 Patent US3069321 A, 1962.
52
53
54
- 55 11. Bonjela. A topical salicylate gel for control of pain and inflammation in dentistry and oral
56
57 medicine. *The Lamp* **1972**, *29* (1), 24.
58
59
60

1
2
3 12. Petkovic, M.; Ferguson, J. L.; Gunaratne, H. Q. N.; Ferreira, R.; Leitao, M. C.; Seddon,
4 K. R.; Rebelo, L. P. N.; Pereira, C. S., Novel biocompatible cholinium-based ionic liquids-
5 toxicity and biodegradability. *Green Chem.* **2010**, *12* (4), 643-649.
6
7

8
9
10
11 13. Sekar, S.; Surianarayanan, M.; Ranganathan, V.; MacFarlane, D. R.; Mandal, A. B.,
12 Choline-based ionic liquids-enhanced biodegradation of azo dyes. *Environ. Sci. Technol.* **2012**,
13 *46* (9), 4902-4908.
14
15

16
17
18
19 14. Li, Z.; Liu, X.; Pei, Y.; Wang, J.; He, M., Design of environmentally friendly ionic liquid
20 aqueous two-phase systems for the efficient and high activity extraction of proteins. *Green*
21 *Chem.* **2012**, *14* (10), 2941-2950.
22
23

24
25
26
27 15. Gorke, J.; Srienc, F.; Kazlauskas, R., Toward advanced ionic liquids. Polar, enzyme-
28 friendly solvents for biocatalysis. *Biotechnol. Bioprocess Eng.* **2010**, *15* (1), 40-53.
29
30

31
32
33 16. Hu, S.; Jiang, T.; Zhang, Z.; Zhu, A.; Han, B.; Song, J.; Xie, Y.; Li, W., Functional ionic
34 liquid from biorenewable materials: synthesis and application as a catalyst in direct aldol
35 reactions. *Tetrahedron Lett.* **2007**, *48* (32), 5613-5617.
36
37

38
39
40
41 17. García-Suárez, E. J.; Menéndez-Vázquez, C.; García, A. B., Chemical stability of
42 choline-based ionic liquids supported on carbon materials. *J. Mol. Liq.* **2012**, *169*, 37-42.
43
44

45
46
47 18. Moriel, P.; García-Suárez, E. J.; Martínez, M.; García, A. B.; Montes-Morán, M. A.;
48 Calvino-Casilda, V.; Bañares, M. A., Synthesis, characterization, and catalytic activity of ionic
49 liquids based on biosources. *Tetrahedron Lett.* **2010**, *51* (37), 4877-4881.
50
51

- 1
2
3 19. Gouveia, W.; Jorge, T. F.; Martins, S.; Meireles, M.; Carolino, M.; Cruz, C.; Almeida, T.
4
5 V.; Araújo, M. E. M., Toxicity of ionic liquids prepared from biomaterials. *Chemosphere* **2014**,
6
7 *104*, 51-56.
8
9
10
11 20. Hou, X.-D.; Li, N.; Zong, M.-H., Facile and simple pretreatment of sugar cane bagasse
12
13 without size reduction using renewable ionic liquids–water mixtures. *ACS Sustainable Chem.*
14
15 *Eng.* **2013**, *1* (5), 519-526.
16
17
18
19 21. Fukaya, Y.; Iizuka, Y.; Sekikawa, K.; Ohno, H., Bio ionic liquids: room temperature
20
21 ionic liquids composed wholly of biomaterials. *Green Chem.* **2007**, *9* (11), 1155-1157.
22
23
24
25 22. Muhammad, N.; Hossain, M. I.; Man, Z.; El-Harbawi, M.; Bustam, M. A.; Noaman, Y.
26
27 A.; Mohamed Alitheen, N. B.; Ng, M. K.; Hefter, G.; Yin, C.-Y., Synthesis and physical
28
29 properties of choline carboxylate ionic liquids. *J. Chem. Eng. Data* **2012**, *57* (8), 2191-2196.
30
31
32
33 23. Vijayaraghavan, R.; Thompson, B. C.; MacFarlane, D. R.; Kumar, R.; Surianarayanan,
34
35 M.; Aishwarya, S.; Sehgal, P. K., Biocompatibility of choline salts as crosslinking agents for
36
37 collagen based biomaterials. *Chem. Commun.* **2010**, *46* (2), 294-296.
38
39
40
41 24. Yu, Y.; Lu, X.; Zhou, Q.; Dong, K.; Yao, H.; Zhang, S., Biodegradable naphthenic acid
42
43 ionic liquids: synthesis, characterization, and quantitative structure–biodegradation relationship.
44
45 *Chem. Eur. J.* **2008**, *14* (35), 11174-11182.
46
47
48
49 25. Mourão, T.; Tomé, L. C.; Florindo, C.; Rebelo, L. P. N.; Marrucho, I. M., Understanding
50
51 the role of cholinium carboxylate ionic liquids in PEG-based aqueous biphasic systems. *ACS*
52
53 *Sustainable Chem. Eng.* **2014**, *2* (10), 2426-2434.
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
26. Taha, M.; Almeida, M. R.; e Silva, F. A.; Domingues, P.; Ventura, S. P. M.; Coutinho, J. A. P.; Freire, M. G., Novel biocompatible and self-buffering ionic liquids for biopharmaceutical applications. *Chem. Eur. J.* **2015**, *21* (12), 4781-4788.
27. Demberelnyamba, D.; Ariunaa, M.; Shim, Y., Newly synthesized water soluble cholinium-purpurin photosensitizers and their stabilized gold nanoparticles as promising anticancer agents. *Int. J. Mol. Sci.* **2008**, *9* (5), 864-871.
28. Dias, A. M. A.; Cortez, A. R.; Barsan, M. M.; Santos, J. B.; Brett, C. M. A.; de Sousa, H. C., Development of greener multi-responsive chitosan biomaterials doped with biocompatible ammonium ionic liquids. *ACS Sustainable Chem. Eng.* **2013**, *1* (11), 1480-1492.
29. Garcia, H.; Ferreira, R.; Petkovic, M.; Ferguson, J. L.; Leitao, M. C.; Gunaratne, H. Q. N.; Seddon, K. R.; Rebelo, L. P. N.; Silva Pereira, C., Dissolution of cork biopolymers in biocompatible ionic liquids. *Green Chem.* **2010**, *12* (3), 367-369.
30. Molyneux, P., The use of the stable free radical diphenylpicrylhydrazyl (DPPH) for estimating antioxidant activity. *Songklanakarin J. Sci. Technol.* **2004**, *26*, 211-219.
31. Blois, M. S., Antioxidant determinations by the use of a stable free radical. *Nature* **1985**, *181*, 1199-1200.
32. Alam, M. N.; Bristi, N. J.; Rafiquzzaman, M., Review on in vivo and in vitro methods evaluation of antioxidant activity. *Saudi Pharm. J.* **2013**, *21* (2), 143-152.
33. AZUR Environmental, MicrotoxOmni™ Software for Windows® 95/98/NT. Carlsbad, CA, U.S.A. 1999.
34. Hochstein, F. A. Water soluble salts of ellagic acid. Patent US3576007 A, 1971.

- 1
2
3 35. John, K. Choline gallate and its preparation. Patent US2589707 A, 1952.
4
5
6
7 36. Lide, D. R.; Milne, G. W. A., Handbook of data on organic compounds. 3rd ed.; CRC
8 Press: Boca Raton, Fla., **1994**; Vol. 1, pp V3:2594.
9
10
11
12 37. Mota, F. L.; Queimada, A. J.; Pinho, S. P.; Macedo, E. A., Aqueous solubility of some
13 natural phenolic compounds. *Ind. Eng. Chem. Res.* **2008**, *47* (15), 5182-5189.
14
15
16
17 38. Marrero, J.; Gani, R., Group-contribution based estimation of pure component properties.
18 *Fluid Phase Equilib.* **2001**, *183–184*, 183-208.
19
20
21
22
23 39. Queimada, A. J.; Mota, F. L.; Pinho, S. P.; Macedo, E. A., Solubilities of biologically
24 active phenolic compounds: measurements and modeling. *J. Phys. Chem. B* **2009**, *113* (11),
25 3469-3476.
26
27
28
29
30
31 40. Klein, R.; Kellermeier, M.; Touraud, D.; Müller, E.; Kunz, W., Choline alkylsulfates –
32 New promising green surfactants. *J. Colloid Interface Sci.* **2013**, *392*, 274-280.
33
34
35
36
37 41. Klein, R.; Tiddy, G. J. T.; Maurer, E.; Touraud, D.; Esquena, J.; Tache, O.; Kunz, W.,
38 Aqueous phase behaviour of choline carboxylate surfactants-exceptional variety and extent of
39 cubic phases. *Soft Matter* **2011**, *7* (15), 6973-6983.
40
41
42
43
44 42. **EC 2007**; p <http://ec.europa.eu/environment/chemicals/reach>.
45
46
47
48 43. Ventura, S. P. M.; e Silva, F. A.; Gonçalves, A. M. M.; Pereira, J. L.; Gonçalves, F.;
49 Coutinho, J. A. P., Ecotoxicity analysis of cholinium-based ionic liquids to *Vibrio fischeri*
50 marine bacteria. *Ecotoxicol. Environ. Saf.* **2014**, *102*, 48-54.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
44. Ventura, S. P. M.; Marques, C. S.; Rosatella, A. A.; Afonso, C. A. M.; Gonçalves, F.; Coutinho, J. A. P., Toxicity assessment of various ionic liquid families towards *Vibrio fischeri* marine bacteria. *Ecotoxicol. Environ. Saf.* **2012**, *76* (1), 162-168.
45. Hernández-Fernández, F. J.; Bayo, J.; Pérez de los Ríos, A.; Vicente, M. A.; Bernal, F. J.; Quesada-Medina, J., Discovering less toxic ionic liquids by using the Microtox[®] toxicity test. *Ecotoxicol. Environ. Saf.* **2015**, *116*, 29-33.
46. Parvez, S.; Venkataraman, C.; Mukherji, S., A review on advantages of implementing luminescence inhibition test (*Vibrio fischeri*) for acute toxicity prediction of chemicals. *Environ. Int.* **2006**, *32* (2), 265-268.
47. Passino, D. R. M.; Smith, S. B., Acute bioassays and hazard evaluation of representative contaminants detected in great lakes fish. *Environ. Toxicol. Chem.* **1987**, *6* (11), 901-907.
48. Koshihara, Y.; Neichi, T.; Murota, S.; Lao, A.; Fujimoto, Y.; Tatsuno, T., Caffeic acid is a selective inhibitor for leukotriene biosynthesis. *BBA-Lipid Lipid Met.* **1984**, *792* (1), 92-97.
49. Yang, W. S.; Jeong, D.; Yi, Y.-S.; Park, J. G.; Seo, H.; Moh, S. H.; Hong, S.; Cho, J. Y., IRAK1/4-Targeted anti-inflammatory action of caffeic acid. *Mediators Inflamm.* **2013**, *2013*, 12.
50. Búfalo, M. C.; Ferreira, I.; Costa, G.; Francisco, V.; Liberal, J.; Cruz, M. T.; Lopes, M. C.; Batista, M. T.; Sforcin, J. M., Propolis and its constituent caffeic acid suppress LPS-stimulated pro-inflammatory response by blocking NF- κ B and MAPK activation in macrophages. *J. Ethnopharmacol.* **2013**, *149* (1), 84-92.
51. Hseu, Y.-C.; Chou, C.-W.; Senthil Kumar, K. J.; Fu, K.-T.; Wang, H.-M.; Hsu, L.-S.; Kuo, Y.-H.; Wu, C.-R.; Chen, S.-C.; Yang, H.-L., Ellagic acid protects human keratinocyte

1
2
3 (HaCaT) cells against UVA-induced oxidative stress and apoptosis through the upregulation of
4 the HO-1 and Nrf-2 antioxidant genes. *Food Chem. Toxicol.* **2012**, *50* (5), 1245-1255.
5
6
7

8
9 52. Chao, P. C.; Hsu, C. C.; Yin, M. C., Anti-inflammatory and anti-coagulatory activities of
10 caffeic acid and ellagic acid in cardiac tissue of diabetic mice. *Nutr. Metab.* **2009**, *6*, 33.
11
12

13
14 53. Barrera, G., Oxidative stress and lipid peroxidation products in cancer progression and
15 therapy. *ISRN Oncol.* **2012**, *2012*, 21.
16
17
18

19
20 54. Borges, A.; Ferreira, C.; Saavedra, M. J.; Simões, M., Antibacterial activity and mode of
21 action of ferulic and gallic acids against pathogenic bacteria. *Microb. Drug Resist.* **2013**, *19* (4),
22 256-265.
23
24
25
26

27
28 55. Wang, K.; Zhu, X.; Zhang, K.; Zhu, L.; Zhou, F., Investigation of gallic acid induced
29 anticancer effect in human breast carcinoma MCF-7 Cells. *J. Biochem. Mol. Toxic.* **2014**, *28* (9),
30 387-393.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table of Contents Graphic and Synopsis



New cholinium-based salts were synthesized and characterized and revealed to display an outstanding water-solubility, and enhanced antioxidant and anti-inflammatory activities.

Title: Enhancing the antioxidant characteristics of phenolic acids by their conversion into cholinium salts.

Authors: Tânia E. Sintra, Andreia Luís, Samuel N. Rocha, Ana I. M. C. Lobo Ferreira, Fernando Gonçalves, Luís M. N. B. F. Santos, Bruno M. Neves, Mara G. Freire, Sónia P. M. Ventura and João A. P. Coutinho.



New cholinium-based salts were synthesized and characterized and revealed to display an outstanding water-solubility, and enhanced antioxidant and anti-inflammatory activities.

128x103mm (79 x 79 DPI)